You are not logged in.

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial

Ghanizadeh,A, Sahraeizadeh,A and Berk,M 2014, A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial, Child Psychiatry & Human Development, vol. 45, no. 2, pp. 185-192, doi: 10.1007/s10578-013-0390-x.

Attached Files
Name Description MIMEType Size Downloads

Title A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial
Author(s) Ghanizadeh,A
Sahraeizadeh,A
Berk,MORCID iD for Berk,M orcid.org/0000-0002-5554-6946
Journal name Child Psychiatry & Human Development
Volume number 45
Issue number 2
Start page 185
End page 192
Total pages 8
Publisher Springer
Place of publication New York, NY
Publication date 2014-04
ISSN 1573-3327
Keyword(s) Aripiprazole
Autism
Clinical trial
Randomized
Risperidone
Treatment
Social Sciences
Science & Technology
Life Sciences & Biomedicine
Psychology, Developmental
Pediatrics
Psychiatry
Psychology
PSYCHIATRY, SSCI
PLACEBO-CONTROLLED TRIAL
PEDIATRIC-PATIENTS
ABERRANT BEHAVIOR
CHILDREN
IRRITABILITY
ADOLESCENTS
Summary Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient's preference and clinical profile.
Language eng
DOI 10.1007/s10578-013-0390-x
Field of Research 110999 Neurosciences not elsewhere classified
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2014, Springer
Persistent URL http://hdl.handle.net/10536/DRO/DU:30067200

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 14 times in TR Web of Science
Scopus Citation Count Cited 18 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 346 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Mon, 08 Dec 2014, 10:55:45 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.